RE:Way, Way too Early for a Buyout, But!!!!It's going to come down to data when determining fair value for the drug / company. Everyone's speculating that data is good based on company going for peer review.. the question now is, how good is the data? In mice the survival rate was increased by 83% when administered with metablok. What's the efficacy in the human body? That's the real question and that will determine where this is headed.